Stemline Therapeutics, Inc.

Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

	The Company
	Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells.

	Platform
	Stemline Therapeutics has developed a Discovery Platform called StemScreen^® to identify novel compounds that target and kill CSCs.

News
&
Events

4/18/2012
Stemline Announces Two Clinical Presentations of SL-701 at AACR

4/3/2012
Stemline Files Registration Statement for Proposed Initial Public Offering

3/15/2012
Stemline Appoints Former CEO of Cephalon, Kevin Buchi, to Its Board of Directors